Enzolytics Inc (OTCMKTS:ENZC) Stock In Focus After Successful Completion of an MTD Tolerability Study

October 6, 2022

It was a momentous day for Enzolytics Inc (OTCMKTS:ENZC) as the company came into the news cycle after it announced that it had been successful in completing the first phase of the animal toxicology studies into its anti-HIV product ITV-1. Trading Data On Wednesday, ENZC stock fell 1.45% to $0.0340 with 5.82 million shares, compared to its average volume of 5.75 million shares. The stock moved within a range of…

Read More >>

OTC Advancers to Watch: ETEK, EPAZ, AIAD, AXXA, ENZC, GYST

January 28, 2022

Yesterday on the OTC Markets, 395,836 trades were executed, 7.8 billion shares trades, for a total of $2.7 billion in market activity. Of the over 4,000 companies listed on the OTC markets, 2,144 closed in the green.  The following companies require your attention. The Graystone Company (OTCMKTS:GYST) is a great place to start, its share price dropped with the crypto crash last week, however, GYST has recovered and closed green…

Read More >>

Enzolytics Inc (OTCMKTS:ENZC) Stock Continues to Trend Lower: Down 30% in a Month

December 30, 2021

Enzolytics Inc (OTCMKTS:ENZC) is partnering with Scendea USA, Inc. to accelerate the clinical trials and production of ITV-1, an anti-HIV drug. Furthermore, the move could speed up market authorization from the Food and Drug Administration (FDA) and the European Medicines Act (EMA). Trading Data On Wednesday, ENZC stock fell 3.43% to $0.0719 with 21.71 million shares, compared to its average volume of 14.21 million shares. The stock has moved within…

Read More >>

OTC Momentum Report: OPTI, TIPS, ENZC, HCMC, IFXY

November 30, 2021

Following were the most active stock movers on Monday. Keep an eye on these stocks this week. Optec International, Inc. (OTCMKTS:OPTI) stock was in action in the previous trading session as the stock fell 21.54% to $0.0102 with over 55.42 million shares traded hands, compared to its average volume of 24.91 million shares. Over the past 52-week, the stock has been moving in a range of $0.0067 – 0.4400. Tianrong…

Read More >>

Enzolytics Inc (ENZC) Stock Attempts To Bounce Back After The Fall

September 15, 2021

There has been no news of any kind with regards to Enzolytics Inc (OTCMKTS:ENZC) for several weeks but the stock was in action in the markets yesterday nonetheless. The Enzolytics stock ended the day yesterday with gains of as much as 9% and in this situation, it might be a good move for investors to perhaps take a closer look at the last important news to have emerged about the…

Read More >>

Enzolytics Inc (OTCMKTS:ENZC) Stock Fell 22% Last Week: Here are the Latest Devlopments

August 23, 2021

Last week the Enzolytics Inc (OTCMKTS:ENZC) stock suffered a slight decline and ended with a loss of 22% last week. However, at the same time, it should be noted that there was no news about the company that might have triggered the selloff last week. In this situation, it might be a good move for investors to perhaps take a look at a development from last month. At the time,…

Read More >>

Enzolytics Inc (OTCMKTS:ENZC) Stock in Focus After The Recent Fall

August 11, 2021

Over the course of the year so far, Enzolytics Inc (OTCMKTS:ENZC) has been one of the more popular stocks among penny stock investors and it has returned considerable gains as well. However, over the course of the past week the situation has been quite different for the Enzolytics stock as it lost as much as 9% during that period. That being said, it should also be kept in mind that…

Read More >>

Enzolytics Inc (ENZC) Stock Falls From The Recent Peak: Time to Buy?

August 2, 2021

Drug development firm committed on commercialising number of proprietary therapeutics for treating debilitating infectious diseases, Enzolytics Inc (OTCMKTS:ENZC) on July 26, 2021 announced signing of a Letter of Intent with Creative Biolabs for finishing joint production as well as commercialisation of HTLV-1 monoclonal antibodies through combination of the technologies. Currently, no effective vaccines exist against HTLV-1 or even antiviral drugs for treating infections caused by virus. Using AI methodology, the…

Read More >>

Enzolytics Inc (OTCMKTS: ENZC) Appoints Steve Sharabura As Subsidiary President

July 30, 2021

Enzolytics Inc (OTCMKTS: ENZC), this week, announced hiring Steve Sharabura as its President for subsidiary RobustoMed, Inc. The subsidiary is based out of Atlanta. RobustoMed, Inc. shall kick off a new model for its business that will focus on developing opportunities for the international partnership. This pertains specifically to product companies and medical development stage drug candidates.  Role of new President for subsidiary Mr. Steve Sharabura is liable for driving…

Read More >>

Enzolytics Inc. (OTCMKTS: ENZC) Advancing its ITC-1 Anti-HIV Therapy to Clinical Trials under EMA Across Europe

July 27, 2021

Enzolytics Inc. (OTCMKTS: ENZC) has finalized plans to advance the previously tested ITV-1 anti-HIV treatment to clinical studies and supply across Europe. Completing the steps will establish the anti-HIV therapy as a potential revenue source, a significant milestone for Enzolytics’ profitability and human health.  Anti-HIV therapy progressing to clinical studies under EMA The anti-HIV therapy had progressed toward Bulgarian Drug Agency certification, but the process was halted before completion. But,…

Read More >>